Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31099935 | 0.86 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL31101666 | 0.86 | CRBN (0.55) | CRBNDDB1POLB | |
| SCHEMBL31099993 | 0.80 | CRBN (0.47) | CRBNDDB1POLB | |
| SCHEMBL31101382 | 0.79 | CRBN (0.47) | CRBNDDB1POLB | |
| SCHEMBL31101156 | 0.76 | CRBN (0.43) | CRBNDDB1POLB | |
| SCHEMBL31101485 | 0.76 | CRBN (0.51) | CRBNDDB1POLB | |
| SCHEMBL31102583 | 0.75 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL31103199 | 0.75 | CRBN (0.47) | CRBNDDB1POLB | |
| SCHEMBL19586225 | 0.75 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL31099629 | 0.74 | CRBN (0.53) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | claimed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |